Description
Setmelanotide
Setmelanotide is a targeted peptide that activates the melanocortin-4 receptor (MC4R), designed specifically to treat rare genetic forms of obesity caused by disruptions in appetite control. Rather than acting through the GLP-1 pathway like more common treatments, it directly influences the brain’s MC4R system to curb intense hunger, enhance energy use, and aid sustained weight management in individuals with certain inherited obesity disorders.
• Status: Approved by the FDA. Evidence level: FDA-approved indication.
• Standard dosage: 2 to 3 mg per day, administered as a once-daily subcutaneous injection.
• Investigated for use in: Genetic forms of obesity and rare metabolic disorders.
Reviews
There are no reviews yet.